Precision medicine in the management of type 2 diabetes

Lancet Diabetes Endocrinol. 2018 Nov;6(11):891-900. doi: 10.1016/S2213-8587(18)30052-4. Epub 2018 Apr 23.

Abstract

The study of type 2 diabetes has been driven by advances in human genetics, epigenetics, biomarkers, mechanistic studies, and large clinical trials, enabling new insights into disease susceptibility, pathophysiology, progression, and development of complications. Simultaneously, several new drug classes with different mechanisms of action have been introduced over the past two decades, accompanied by data about cardiovascular safety and non-glycaemic outcomes. In this Review, we critically examine the progress and integration of this new science into clinical practice, and review opportunities for enabling the use of precision medicine in the diagnosis and treatment of type 2 diabetes. We contrast the success in delivering personalised medicine for monogenic diabetes with the greater challenge of providing a precision medicine approach for type 2 diabetes, highlighting gaps, limitations, and areas requiring further study.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / diagnosis*
  • Diabetes Mellitus, Type 2 / genetics
  • Diabetes Mellitus, Type 2 / therapy*
  • Genetic Predisposition to Disease
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Pharmacogenetics
  • Precision Medicine*
  • Treatment Outcome

Substances

  • Hypoglycemic Agents